SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTIC, LTHM, SYNH, FRG

NEW YORK, May 10, 2023

CTI BioPharma Corp. (NASDAQ: CTIC)'s sale to Swedish Orphan Biovitrum AB for $9.10 per share. If you are a CTI BioPharma shareholder, click here to learn more about your rights and options.

Livent Corporation (NYSE: LTHM)'s merger with Allkem. Upon completion of the proposed transaction, Livent shareholders are expected to own approximately 44% of the combined company. If you are a Livent shareholder, click here to learn more about your rights and options.

Syneos Health, Inc. (NASDAQ: SYNH)'s sale to a consortium of affiliates of Elliott Investment Management, Patient Square Capital, and Veritas Capital for $43.00 per share in cash. If you are a Syneos shareholder, click here to learn more about your rights and options.

Franchise Group, Inc. (NASDAQ: FRG)'s sale to members of the senior management team of Franchise Group led by Brian Kahn, the Company's Chief Executive Officer, and a consortium including B. Riley Financial, Inc. and Irradiant Partners, for $30.00 in cash per share. If you are a Franchise Group shareholder, click here to learn more about your rights and options. 

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.